Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thyroid Cancer Affiliated to a social security regimen ; 2. Patients with histologically confirmed differentiated thyroid cancer (papillary, follicular including Hurthle cell or poorly differentiated) ; 3. Iodine refractory disease defined by the absence of radioiodine uptake in at least one lesion or progression of the disease within 14 months after a radioactive iodine (RAI) treatment or persistent disease after the administration of a cumulative activity of 22GBq I 131 ; 4. Age ≥18 years ; 5. Eastern Cooperative Oncology Group performance status 0-2 ; 6. Life expectancy longer than 3 months ; 7. Presence of at least one bone metastasis visible on CT scan or axial skeleton (AS) MRI and not requiring urgent locoregional treatment ; 8. Presence of at least one bone metastasis with uptake on FDG PET/CT ; 9. Presence of at least one bone metastasis with increased uptake on 99mTc HMDP bone scintigraphy or FNa PET/CT 10. Low likelihood of an indication for systemic treatment within the next 6 months, as defined by the absence of soft tissue distant metastases or by the presence of only small (<1cm) soft-tissue metastases, or larger (>1 cm) but stable soft tissue metastases within 6 months prior to in the present protocol ; 11. Adequate haematological (neutrophils ≥1,5×109/L; platelets ≥100×109/ L; haemoglobin > 9g/dL), renal (creatinine <1,5×upper limit of normal range), and hepatic (total bilirubin < 1.5 institutional upper limit of normal), aspartate aminotransferase and alanine aminotransferase <2,5×upper limit of normal range in the absence of liver metastases or <5×upper limit of normal range in case of liver metastases) functions ; 12. Patients receiving bisphosphonates or anti-RANK ligand (Denosumab) are allowed but patients should have received at least 2 administrations prior to Radium-223 administration and these treatments will be continued during Radium-223 treatment ; 13. Blood negative pregnancy test in women of childbearing potential within 30 days prior to treatment initiation. Both men and women (of childbearing potential) who are sexually active must use adequate contraception during and for at least 6 months post-treatment ; 14. Patient who is fully informed, able to comply with the protocol and who signed the informed consent  Patients with another malignancy that is not in remission for at least 2 years (except for in situ cervix uterine cancer, basocellular skin cancer) ; 2. Treatment with any investigational drug or with a TKI within the previous 4 weeks, or planned during the treatment period ; 3. Treatment with cytotoxic chemotherapy within the previous 4 weeks, or planned during the treatment period, or failure to recover from adverse events due to cytotoxic chemotherapy administered more than 4 weeks before the study initiation ; 4. Previous systemic therapy with radionuclides, including strontium-89, samarium-153, rhenium-186, rhenium-188 or radium-223 ; 5. Patients with imminent or established spinal cord compression based on clinical findings and/or MRI and/or immediate need for local radiotherapy ; 6. Patients with progressive visceral metastases according to 1.1 assessed by CT scan and/or symptomatic brain metastases within 6 months prior to study initiation ; 7. Patient already included in other clinical trial ; 8. Pregnant or breast feeding women ; 9. Fecal or urinary unmanageable incontinence ; 10. Bone marrow dysplasia, uncontrolled diabetes or infection, NYHA Class III or IV cardiac disorders, fecal incontinence and symptomatic intestinal disease (such as Crohn disease or ulcerative colitis)